Clinical results of radiation therapy for localized gastric lymphoma

H. Mihara1, K. Katsui1, K. Hisazumi1, N. Katayama1, M. Takemoto2, M. Iwashiro1, Y. Kawahara1, H. Okada1, S. Kanazawa1
1Okayama University Hospital, Radiology, Okayama, Japan
2Japanese Red Cross Society Himeji Hospital, Radiology, Okayama, Japan

Purpose or Objective: To report the outcome of localized gastric lymphoma treated with radiation therapy.

Material and Methods: This study included 27 patients (14 men, 13 women; median age 67 years, range 37–83 years) with localized gastric lymphoma and who received radiation therapy between January 2005 and December 2014 at our institution. Patients with a follow-up period <6 months were excluded. Twenty-three patients were mucosa-associated lymphoid tissue (MALT) lymphoma, and 4 patients were diffuse large B-cell lymphoma (DLBCL). The stage was classified by Lugano international conference classification. All patients with MALT lymphoma were Stage I. In DLBCL, 2 patients were Stage I, and 2 patients were Stage II. The median radiation dose in MALT lymphoma was 30Gy (range, 7.5–30), and in DLBCL was 40.5Gy (range, 30–40.5). All MALT lymphoma patients with Helicobacter pylori-positive were received eradication therapy before radiation therapy. All patients with DLBCL were treated with chemotherapy followed by radiation therapy. Acute and late adverse events were evaluated in accordance with Common terminology criteria for adverse events, version 4.0. The local recurrence rate was calculated using Kaplan-Meier analysis.

Results: The median follow-up period was 58 months (range, 6.0–120.0). Local recurrence occurred in only 2 patients with MALT lymphoma. No distant recurrence was observed. Local recurrence rate in MALT lymphoma was 91% at 1 year, 91% at 3 years. In acute adverse events, 5 patients had grade 3 white blood cell decreased, 1 patient had grade 4 white blood cell decreased and platelet count decreased, and 1 patient had grade 3 anorexia. One patient with MALT lymphoma could not achieve the planned radiation therapy because of grade 4 white blood cell decreased and platelet count decreased. There was no grade 3 or greater late adverse event. One patient with MALT lymphoma suffered from gastric cancer, and underwent endoscopic excision. No patients died of gastric lymphoma. One patient died of lung cancer.

Conclusion: Radiation therapy for localized gastric lymphoma was safe and effective. Our result was similar to previous reports.

Second cancer in Primary Mediastinal Lymphoma treated with MACOP-B ± R and mediastinal radiotherapy

V. De Sanctis1, M. Alfo2, A. Di Rocco3, A. Ansuinelli4, E. Russo5, M. Osti6, M. Valeriani7, G. Minniti8, L. Grapulin9, D. Musio10, S. Bracci11, A. Spagnoli12, M. Moleti13, V. Tombolini14, M. Martelli15
1Sapienza Università di Roma, Department of Medicine and Pharmaceutical Sciences, Rome, Italy
2Sapienza Università di Roma, Department of Surgery and Translational Medicine, Rome, Italy
3Sapienza Università di Roma, Department of Statistical Sciences, Rome, Italy
4Sapienza Università di Roma, Department of Cellular Biotechnologies and Hematology, Rome, Italy
5Sapienza Università di Roma, Department of Radiological-Oncological and Anatomopathological Sciences, Rome, Italy

Purpose or Objective: To assess the incidence of second cancer in a mono-institutional cohort of long-time surviving Primary Mediastinal B Cell Lymphoma (PMBCL) patients treated with combined radio-chemo-immunotherapy.

Material and Methods: Between 1991 and December 2006, 107 consecutive untreated patients (pts) with PMBCL were treated at our Departments. Ninety-two/107 pts were evaluable for the second cancer incidence. All patients were treated with standard Methotrexate, Adriamycin, Cyclophosphamide, Vincristine, Prednison and Bleomycin (MACOP-B) ± Rituximab; all patients underwent mediastinal radiation therapy (RT) at a dose of 30-36 Gy.

Results: At the end of combined treatment, the overall response rate (ORR) including CR+Cru/PR was 91.3% while 7 (7.6 %) patients showed progressive disease. Nine/84 (9.7%) patients relapsed within 10 months (range 3-10 months) from the end of therapy. After a median follow-up of 142 months (1-212 months), the actuarial 15-year OS and PFS were 87% and 84%, respectively. We recorded secondary malignancies in 3/80 long-surviving patients (3.75%) with cumulative incidence of thyroid and Acute Myeloid leukemia of 3.47 at 15 years and with a 20-year second cancer-free survival of 82%. We observed 2 papillary thyroid cancers with a Standardized Incidence Ratio of 7.97 and with an Absolute Excess Risk of 1.84. Moreover, we observed 1 Acute Myeloid Leukemia (AML) versus 0.015 expected cases with a SIR of 66.53 and with an AER of 10.05. No breast cancer occurred.

Conclusion: Combined modality treatment of chemotherapy, with/without Rituximab and mediastinal RT was related to a